Skip to main content
Journal cover image

Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy

Publication ,  Journal Article
Freedman, SA; Bialy, T; Abramova, L; Chen, S
Published in: Journal of the American Academy of Dermatology
March 2004

Duke Scholars

Published In

Journal of the American Academy of Dermatology

DOI

ISSN

0190-9622

Publication Date

March 2004

Volume

50

Issue

3

Start / End Page

P5 / P5

Publisher

Elsevier BV

Related Subject Headings

  • Dermatology & Venereal Diseases
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Freedman, S. A., Bialy, T., Abramova, L., & Chen, S. (2004). Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy. Journal of the American Academy of Dermatology, 50(3), P5–P5. https://doi.org/10.1016/j.jaad.2003.10.023
Freedman, Stacey A., Tracy Bialy, Liana Abramova, and Suephy Chen. “Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy.” Journal of the American Academy of Dermatology 50, no. 3 (March 2004): P5–P5. https://doi.org/10.1016/j.jaad.2003.10.023.
Freedman SA, Bialy T, Abramova L, Chen S. Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy. Journal of the American Academy of Dermatology. 2004 Mar;50(3):P5–P5.
Freedman, Stacey A., et al. “Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy.” Journal of the American Academy of Dermatology, vol. 50, no. 3, Elsevier BV, Mar. 2004, pp. P5–P5. Crossref, doi:10.1016/j.jaad.2003.10.023.
Freedman SA, Bialy T, Abramova L, Chen S. Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy. Journal of the American Academy of Dermatology. Elsevier BV; 2004 Mar;50(3):P5–P5.
Journal cover image

Published In

Journal of the American Academy of Dermatology

DOI

ISSN

0190-9622

Publication Date

March 2004

Volume

50

Issue

3

Start / End Page

P5 / P5

Publisher

Elsevier BV

Related Subject Headings

  • Dermatology & Venereal Diseases
  • 3202 Clinical sciences
  • 1103 Clinical Sciences